Parkinsonian features may respond variably to dopaminergic therapy; dystonia can be approached with anticholinergics or botulinum toxin in focal forms; chorea may respond to VMAT-2 inhibitors or atypical antipsychotics; seizures are treated with standard antiseizure medications, avoiding agents that exacerbate dystonia when possible. The gene discussed is SLC18A2; the disease is Dystonia.